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Abstract
Introduction: The aim of this study was to compare the epidemiology, risk factors, severity and outcome of two
types of ICU-treated candidemias: namely, ICU-acquired candidemia (acquired after 48-hour ICU stay) (ICUAC
group), and those needing ICU treatment for candidemia acquired before ICU admission or during the first 48-hour
ICU stay (non-ICUAC group).
Methods: A retrospective cohort study was conducted between 2000 and 2009 in a mixed tertiary ICU among
patients with blood-culture-confirmed candidemia.
Results: The study involved 82 patients (53 men). The ICUAC group consisted of 38 patients (46.3%) and the non-
ICUA group included 44 patients (53.6). The ICUAC group had undergone previous surgery more often and had
ICU stays that were 3.7 times longer than the non-ICUAC group, whose members more often had co-morbidities
(95.6% versus 73.7%, P = 0.001). The ICUAC group had significantly more frequent organ failures with
cardiovascular, renal, central nervous and coagulation systems than the non-ICUAC group. ICU, hospital and one-
year mortality rates did not differ between the groups (23%, 36.8% and 65.8%, respectively, in the ICUAC group
and 26%, 44.4% and 64.4%, respectively, in the non-ICUAC group). Among patients with APACHE II scores greater
than 25, the ICUAC group had lower one-year mortality (65.0% versus 87.5%). Among patients with APACHE II
scores of 25 or less, the ICUAC group had higher mortality (66.7% versus 50.0). Candida albicans was most
common cause of candidemia in both groups (76.3% and 68.9%, respectively).
Conclusions: More than half of the ICU-treated candidemias were acquired prior to admission to the ICU. Patients
with ICU- and non-ICU-acquired candidemias had different risk factors and different needs for ICU resources.
Hospital mortality was similar in both groups; however, the groups had different mortality rates when the severity
of disease and underlying diseases were taken into account.
Introduction
Candida species are among the most common microbes
causing severe infections in patients in ICUs. Recent Eur-
opean publications of the causes of bloodstream infec-
tions (BSI) have listed Candida species as between the
fifth and tenth most common causative pathogen [1].
Candidemia is associated with increased overall morbid-
ity and attributable mortality, longer duration of ICU
stay, as well as increased cost [2-5].
C. albicans has been the most common isolate (60% to
70%) among patients with ICU-acquired candidemia, fol-
lowed by C. glabrata (15% to 20%). Some publications
have shown an increase of candidemias with non-albicans
Candida species, although contrary results have also
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Among ICU patients, candidemia is typically a late-
onset nosocomial infection. As far as can be determined,
few studies have investigated the characterization types
of candidemias in the ICU. Specifically, this refers to
candidemias acquired prior to ICU admission (non-
ICUAC group) or within 48 hours of admission and
those who have an ICU-acquired candidemia (ICUAC
group), that is, more than 48 hours after ICU admission
[1,11]. The present study examined whether these two
candidemia groups have different risk factors, severity,
outcomes or resource utilization or the spectrum of
Candida species.
Materials and methods
Study location and design
The study was conducted at Oulu University Hospital, a
900-bed tertiary-level teaching hospital. The mixed medi-
cal-surgical ICU is an 11-bed unit with three two-bed
rooms, one three-bed room and two single-bed rooms.
This ICU has between 750 and 800 annual admissions.
Data from patients admitted into the medical-surgical
ICU between 2000 and 2009 were evaluated retrospec-
tively. The list of patients with positive blood cultures for
Candida species was obtained from the register of the
Clinical Microbiology Laboratory of Oulu University
Hospital. Patients were divided into two groups: the non-
ICUAC group, in which candidemia was diagnosed
before ICU admission or during the first 48 hours after
ICU admission; and the ICUAC group, in which candide-
mia was diagnosed more than 48 hours after ICU admis-
sion. We consulted the chief of the Ethical Committee
and she noted that because the study design was a regis-
ter-based survey with no contact or consequences to the
patients approval from the Ethical Committee was
unnecessary.
Study parameters
The following information was collected for all study
patients: age, gender, severity of underlying diseases,
organ dysfunctions on admission as assessed by the
Acute Physiology and Chronic Health Evaluation index
(APACHE II) [12] and Sequential Organ Failure Assess-
ment Score (SOFA) with six different types of organ
failure [13], smoking habits, alcohol or drug abuse, pre-
sence of ischemic heart disease, chronic obstructive pul-
monary disease (COPD), diabetes mellitus or hepatic
failure, underlying hematological or other malignancy,
recent use of immunosuppressive therapy, elective or
emergency operations during the preceding 30 days, and
previous antimicrobial therapy. The length of stay in the
ICU and in the hospital was recorded, as was ICU and
hospital mortality. Post-discharge mortality data were
obtained from the Central Statistical Office of Finland
on 28 June 2010.
Microbiological analysis
Blood cultures were carried out by an automated contin-
uous monitoring screening system of BacT/Alert (bio
Mérieux, Marcy-l’Etoile, France). Between 2000 and
2005, 10 ml of venous blood was taken into standard
aerobic and anaerobic blood culture bottles if neither
antimicrobials nor antineoplastics were used during the
preceding seven days; otherwise, the samples were cul-
tured in in bottles containing neutralizing agents (Eco-
sorb) for antimicrobials. Corresponding, new FA/FN
bottles have been used since 1999 for all patients sus-
pected of having candidemia, and for all patients, since
2006. Until the end of October 2008, blood samples were
drawn at the time clinical sepsis was documented and
from between 30 minutes and two hours thereafter.
From November 2008, both sets of blood samples were
taken at the same time but from different blood vessels.
The blood bottles were screened for up to five days and,
in case there was a suspicion of slowly growing bacterial
and yeast pathogens, up to 14 days. Positive blood cul-
tures were gram-stained and subcultured. Commercial
kits identified yeast growth as C. albicans or yeast, not
albicans, within a few hours and further as species level
within two days by a API ID 32 C (bioMérieux). Positive
blood cultures were gram-stained and subcultured. Com-
mercial kits identified yeast growth as C. albicans or
non- albicans within a few hours, and further as species
level within two days. E-test was used to test antifungal
susceptibility to fluconazole, voriconazole, caspofungin
and amphotericin B. Bacterial and yeast findings were
also reported immediately by phone to the clinician.
Data registration and statistical analysis
The data were entered into a SPSS database (SPSS Data
Entry, version 2.0, SPSS Inc., Chicago, IL). Summary statis-
tics for continuous or ordinal variables are expressed as
the median with the 25th to 75th percentile. Kaplan-Meier
survival curves and log-rank test results are presented for
simple comparisons between non-ICU and ICU-acquired
candidemia groups. The APACHE II score (< 25 or > 25)
was used as an adjusting factor in Cox’s proportional
hazards model to further evaluate the group effect in one-
year mortality. Two-tailed P-values are reported, and the
analyses were performed by the SPSS (version 18.0, SPSS
Inc., Chicago, IL) software.
Results
Characteristics of study groups
The total study population consisted of 82 patients with
candidemia: 38 in the ICUAC group and 44 in the non-
ICUAC group. The incidence of ICUAC per 1,000 patient
days varied from 0.19 (in 2005) up to 0.9 (in 2000 and
2009). The proportion of patients with non-ICUAC
slightly increased during the study years, from 50% (19/38)
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during the first five-year period to 58% (26/44) during the
last five years.
Table 1 presents the main demographic data of the
groups. Patients in the non-ICUAC group more often had
underlying co-morbidities (96% versus 46%, P = 0.01),
especially malignancies (29% versus 11%, P = 0.04). As
Table 1 also shows, patients in the non-ICUAC group had
experienced recent surgery significantly less often (60%
versus 84%, P = 0.016) and they also had central venous
catheters (64%) less often than patients in the ICUAC
group (100%, P < 0.001). In both study groups, the median
time between previous surgery and candidemia was one
week; gastrointestinal surgery (39% of patients) was most
common, followed by plastic surgery (8% of patients).
Patients in the ICUAC group had received pre-emptive
fluconazole treatment significantly more often (13.3% ver-
sus 40%, P = 0.007). Most patients had also been on anti-
bacterial treatment before candidemia. The most common
antibacterials used in the ICUAC group and the non-
ICUAC group were as follows: piperacillin/tazobactam in
22 (58%) and 24 patients (52%), second generation cepha-
losporins in 15 (39%) and 19 patients (41%), fluoroquino-
lones in 15 (39%) and 6 (13%) patients, and carbapenems
in 8 (21%) and 6 patients (13%), respectively.
As Table 2 shows, the median APACHE II or SOFA
scores did not differ statistically between the groups. How-
ever, when six different organ failures were compared
between the two candidemia groups (Table 3), the patients
in the ICUAC group had significantly higher maximum
SOFA scores in coagulation (P = 0.012), cardiovascular
(P = 0.010), central nervous system (P = 0.000) and renal
systems (P = 0.005). The median duration of hospital stay
before ICU admission was 1.0 day (with 25 and 75 percen-
tiles 0.0 to 2.0) in the ICUAC group and 7.5 days (1.0 to
16.0) in the non-ICUAC group. The median duration of
hospital stay before positive blood cultures was 12 days
(7.0 to 19.0) in the ICUAC group and 11 days (3.0 to 17.0)
in the non-ICUAC group.
Laboratory data and clinical characteristics
The ICUAC group had a higher body temperature on
the day of positive blood culture than the non-ICUAC
group (38.8°C versus 38.3°C, P = 0.03). On the other
hand, C-reactive protein (CRP) and leukocyte counts on
the day of positive blood culture did not differ between
the groups (CRP was 126 mg/L in the ICUAC group
and 165 mg/L in the non-ICUAC group (P = 0.7) and
leukocyte count was 11.3 x109/L versus 9.4 x109/L,
respectively). Abnormal renal function (creatinine > 90
mmol/L in women and > 100 mmol/L in men) was
noticed in 16 patients (42%) in the ICUAC group and in
23 patients (49%) in the non-ICUAC group. In the
ICUAC group, CRP reached its peak on day three after
positive blood culture: 160 mg/L (with 25 percentile of
100 mg/L and 75 percentile of 232 mg/L) while CRP in
the non-ICUAC-group peaked on the day of blood cul-
ture at 165 mg/L (with 25 percentile of 61 mg/L and 75
percentile of 195 mg/L).
Distribution of candida species
C. albicans was the most common isolate in both groups
across the entire study period (Table 4). The proportion
of non-albicans species was 26.7% in the ICUAC group
and 31.1% in the non-ICUAC group. The most common






Male (%) 27 (71) 27 (61) 0.35
Age years 63 (45 to 69) 64 (56 to 75) 0.194
Co-morbidities (%) 28 (73.7) 43 (95.6) 0.01
Distribution (%)
- Diabetes 5 (13.2) 7 (15.6) > 0.9
- Malignancy 4(11) 13 (29) 0.04
- COPD 4 (1.5) 6 (13.3) > 0.9
- Hepatic cirrhosis 1 (2.4) 4 (8.9) 0.39
- IHD 9 (23.7) 16 (35.6) 0.337
- Alcohol abuse 9 (32.1) 7 (20.6) 0.386
Previous surgery (%) 32 (84.2) 27 (60) 0.016
- Intra-abdominal surgery 16 (50) 16 (39) 0.47
Central venous catheter (%) 38 (100) 29 (64) < 0.001
Duration of central venous catheter before positive BC (days) 7 (6 to 11) 7 (6 to 7) 0.84
Previous antibacterial treatment (%) 37 (97.4) 43 (95.5) > 0.9
Previous fluconazole prophylaxis (%) 15 (39.5) 6 (13.3) 0.010
Values are presented as median (with 25th to 75th percentiles) or as the number (percentage) of patients. BC, blood culture; COPD, chronic obstructive pulmonary
disease; IHD, ischemic heart disease; TIA, transient ischemic attack.
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non-albicans species was C. glabrata. There was a rela-
tively small and non-significant decrease of non-albicans
species in the ICUAC candidemia group between the
first five years and the last five years (26.3% versus 21.1%,
respectively) and, on the contrary, a small non-significant
increase in the non-ICUAC group (26.3% versus 34.6%,
respectively).
Antifungal treatment
The median duration of the antifungal treatment was 22
days in patients in the ICUAC group and 24 days in the
non-ICUAC group. The most common antifungal used
was fluconazole (38 patients (73%) in the ICUAC group
and 35 (77%) in the non-ICUAC group), followed by
liposomal amphotericin (13 patients (34%) in the ICUAC
group and 16 patients (35%) in the non-ICUAC group)
and echinocandins (12 patients (31%) and 18 patients
(40%), respectively). The median time between positive
blood cultures and the beginning of antifungal treatment
was less than 24 hours (with 25th percentiles 0 to 2-days
in both groups) and there were no differences between
the groups. Patients with fluconazole prophylaxis were
not included in this analysis. Eighteen patients out of 82
(23% of the whole study population) developed break-
through candidemia during fluconazole treatment. Of
these 18 patients, 16 (89%) had previously been operated
on and two (11%) had malignancies. The median dura-
tion of the fluconazole prophylaxis was 7.0 days.
Fluconazole-resistant C. albicans or glabrata was found
in ten patients, six of whom were in the non-ICUAC
group and four in the ICUAC group. Four out of ten
patients had previously received fluconazole. Hospital
mortality was significantly higher among patients with
candidemia due to fluconazole-resistant candida than
patients with candidemia due to fluconazole-sensitive can-
dida (90% versus 37%, P < 0.002).
Outcome
As Table 5 shows, the length of hospital stay did not differ
between the groups. The median duration of hospital stay
before ICU admission was 1.0 day (with 25th to 75th per-
centiles 0.0 to 2.0) in the ICUAC group and 7.5 days
(1.0 to 16.0) in the non-ICUAC group (P < 0.0001). The
median duration of hospital stay before positive blood cul-
tures was 12 days (7.0 to 19.0) in the ICUAC group and
11 days (3.0 to 17.0) in the non-ICUAC group. Among the
patients in the ICUAC group, the time between ICU
admission and the onset of candidemia was 8.0 days (1.0
to 12.0).
The length of stay in the ICU was significantly longer
among the surviving patients with ICU-acquired infec-
tion (Table 4). The ICU mortality did not differ greatly






APACHE II on admission 27 (18 to 29) 23.5 (18.5 to 29) 0.79
APACHE II on the day when BC positive 20.5 (16.5 to 26) 22.5 (19 to 27) 0.34
SOFA on admission 9 (7 to 11) 8.5 (5 to 11) 0.281
SOFA on the day when BC positive 10 (7 to 13.5) 7 (5 to 11) 0.172
Values are presented as a median (with 25th to 75th percentile) or as the number (%) of patients. APACHE II, Acute Physiology and Chronic Health Evaluation
score; BC, blood culture; ICUACG, ICU-acquired candidemia group; non-ICUACG, non-ICU-acquired candidemia group; LOS, length of stay; SOFA, Sequential Organ
Failure Assessment scale.
Table 3 Comparison of the highest SOFA-scores in the






Respiratory 3 (2 to 4) 3 (2 to 3) 0.064
Coagulation 2 (1 to 3) 1 (0 to 2) 0.012
Liver 2 (1 to 3) 1 (0 to 3) 0.097
Cardiovascular 4 (3 to 4) 3 (3 to 4) 0.010
CNS 3 (2 to 4) 1 (0 to 3) 0.000
Renal 4 (0 to 4) 1 (0 to 3) 0.005
Values are presented as medians (with 25th to 75th percentiles). CNS, central
nervous system; ICUACG, ICU-acquired candidemia group; non-ICUACG, non-
ICU-acquired candidemia group; SOFA, Sequential Organ Failure Assessment
scale.







C. albicans 29 (76.3) 31 (68.9) 0.47
C. non- albicans 9 (26.7) 14 (31.1)
- C. glabrata 5 10
- C. parapsilosis 3 2
- others 1 2
C. albicans
- 2000 to 2004, n = 37 14 (73.7) 14 (77.8) > 0.9
- 2005 to 2009, n = 45 15 (78.9) 17 (65.4)
C. non- albicans
- 2000 to 2004 5 (26.3) 5 (26.3) 0.51
- 2005 to 2009 4 (21.1) 9 (34.6)
Other species were: C. guillerimondii, C. krusei and C. tropicalis. ICUACG, ICU-
acquired candidemia group; non-ICUACG, non-ICU-acquired candidemia
group.
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between the groups (23% versus 26%), and the same
applies for hospital mortality (36.8% versus 44.4%) and
one-year mortality (65.8% versus 64.4%). The majority of
the deaths (55.4%) occurred during the first 60 days
after positive blood cultures in both groups (Figure 1).
In the ICUAC group, one-year mortality among patients
who had APACHE II scores of 25 or less was higher
(66.7% versus 50.0%, Figure 1), while the mortality was
lower among patients with APACHE II scores greater
than 25 (65.0% versus 87.5%, Figure 2). This result was
supported by the multivariate Cox model with the inter-
action term (group x APACHE II score HR 2.7; 95%
confidence interval 0.92 to 8.1).
Discussion
The results of this study show that more than half of
the candidemia patients treated in the ICU acquired the
infection before ICU admission and more often had co-






Length of hospital stay (days) in surviving patients 38.0 (22 to 59) 40.0 (22 to 57) 0.762
Length of ICU stay (days) in surviving patients 16.0 (11 to 30) 4.0 (2 to 9) < 0.001
ICU mortality 8 (23) 12 (26)
28-day mortality 8 (21.1) 14 (31.1) 0.33
Hospital mortality 14 (36.8) 20 (44.4) 0.51
One-year mortality 25 (65.8) 29 (64.4) > 0.9
ICUACG, ICU-acquired candidemia group; non-ICUACG, non-ICU-acquired candidemia group.
Figure 1 Kaplan-Meier one-year survival curves in ICUACG (ICU acquired candidemia group) and the non-ICUACG (non-ICU acquired
candidemia group) for patients with APACHE II (Acute Physiology and Chronic Health Evaluation index) scores on admission of ≤ 25.
The APACHE II score adjusted P-value according to log-rank test is 0.60.
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morbidities, especially malignancies. On the other hand,
the real ICU-acquired candidemia patients had under-
gone surgery more often and they all had central lines.
Moreover, ICUAC patients had statistically higher maxi-
mum SOFA scores in four of six organ systems.
This study has several strengths. Earlier literature of
ICU-treated candidemia did not compare the epidemiol-
ogy and outcome of non-ICU onset and ICU-acquired
candidemias. The case definition required blood culture
confirmation for candidemia. All blood cultures had been
processed in the same microbiological laboratory, which
is accredited by the Finnish Lab Quality-system. More-
over, the study followed the long-term outcome of candi-
demia patients for up to one year. The study also has
some limitations. Due to its retrospective approach, some
essential information was probably overlooked. More-
over, the study was only performed in a single mixed
ICU, so the results cannot be directly extrapolated to
other types of intensive care units. Furthermore, the rela-
tively small study groups did not seem to justify the use
of multivariate analysis for the risk factors of mortality.
The recent literature includes some reports of increas-
ing figures of the overall incidence of candidemia, as well
as ICU-acquired candidemia since 2000 [3,8]. In the pre-
sent series, the incidence of ICU-acquired candidemia
was quite stable during the relatively long study period.
Data from the National Nosocomial Infection System
(NNIS) survey showed a decline in the frequency of can-
didemia among ICU patients in the United States, while
the burden of invasive candidiasis is shifting from the
ICU to the general hospital wards [14]. Another report
from Italy also concluded that candidiasis can no longer
be considered to be just an ICU-related infection and
that efforts to design preventive and diagnostic strategies
Figure 2 Kaplan-Meier one-year survival curves in ICUACG (ICU acquired candidemia group) and the non-ICUACG (non-ICU acquired
candidemia group) for patients with APACHE II scores on admission > 25. The APACHE II score adjusted P-value according to log-rank test
is 0.60.
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must be expanded to include other at-risk populations
and hospital environments [15]. Recent literature has
also reported that nearly one-quarter of candidemias
were healthcare-associated [16]. These findings are in
keeping with ours, where less than half of the patients
needing ICU treatment due to candidemia belonged to
the ICUAC group. In our series, ten out of 45 patients
(22%) in the non-ICUAC group had acquired healthcare-
associated candidemia before admission (data not
shown). Besides, the number of patients in the non-
ICUAC group was almost 1.5 times higher during the
last five-year period than in the first five-year period of
the study. One explanation for this could be more active
use of blood cultures for the diagnosis of infections in
the wards of the studied hospital, where the number of
obtained blood cultures increased 2.3-fold from 2000 to
2009 (according to the register of the Microbiology
Laboratory).
As far as can be ascertained, few publications have
compared ICU-acquired candidemia patients with non-
ICU-acquired candidemia cases needing ICU treat-
ment. For example, a large multicenter study with 300
ICU-treated patients in French ICUs did not reveal
this specific topic [17]. In the present series, the ICU
stays of the ICUAC group were 3.7 times longer than
patients in the non-ICUAC group. Moreover, the
ICUAC group had statistically higher maximum SOFA
scores concerning coagulation, cardiovascular, central
nervous and renal systems. When the two time periods
were compared, similar results concerning the circula-
tion and renal systems were observed during the last
period.
The risk profiles for candidemia were also different in
those groups that had an impact, for example, on pre-
vention of those infections. Patients with ICU onset can-
didemia had a history of previous surgery significantly
more often, especially intra-abdominal operations. In
addition, they all had central venous catheters. On the
other hand, patients in the non-ICUAC group more
often had underlying diseases, such as malignancies. The
risk of candidemia in those patients is more probably
due to the immunosuppressive condition, which is often
hard to influence by infection control methods [18].
Despite high severity scores on admission, the hospital
mortality of candidemia patients treated in the ICU was
only 43.4% in the present series, with the similar rates
in both groups (36.8% versus 44.4%) being almost iden-
tical to the mortality rate of 42.6% in the EPIC II study
[19]. Hospital mortality in other studies has varied from
26% to 62% among patients with C. albicans fungemia,
and from 34% to 90% among patients with non-albicans
candidemia [6,11,20]. Delayed administration of antifun-
gals had been reported to be a risk factor for worse out-
come [21-23]. In the present series, the median time
between taking positive blood cultures and starting anti-
fungal treatment was less than 24 hours in both survey
groups. Another explanation of favorable outcome could
be the relatively low proportion of non-albicans species.
It is important to note that although almost 40% of
patients in the ICUAC group had prophylactic or pre-
emptive treatment with fluconazole, they developed a
breakthrough invasive candida infection. Breakthrough
candemia during fluconazole treatment has been
reported, for example, in association with hematological
malignancies [24]. Similar breakthrough invasive candi-
dal infections have even been reported during echino-
candin treatment [25-27].
The existing literature has sparse information about
the long-term outcome of candidemia patients. In a
nationwide survey of candidemia in Israel, one-year
mortality was 31.9% [28] and 90% of patients died
within 90 days after the identification of candidemia. In
the present ICU series, one-year mortality was twice as
high (65.9%), while 60.2% of the deaths occurred within
90 days. Non-ICUAC patients with APACHE scores
greater than 25 on admission had higher long-term
mortality which reflects the importance of underlying
co-morbidities in survival.
The trend of changes in the distribution of C. albicans
and non-albicans species has been controversial in the
recent literature. In a recent study from Brazil, the propor-
tion of non-albicans species was exceptionally high, at
82% [29]. In harmony with most other recent publications,
C. albicans was the most common species in the present
study population. In fact, there was even a small but insig-
nificant decrease of non-albicans species in the ICUAC
candidemia group and a small increase of these species in
the non-ICUAC group. It has been noted that even a
three-year period with routine fluconazole prophylaxis for
selected Surgical ICU patients did not cause an increase of
C. glabrata colonization or invasive candidasis due to C.
glabrata [30].
In conclusion, the present study shows that the major-
ity of ICU treated candidemias are actually acquired
before ICU admission. The ICUAC group had more
specific organ failures than the non-ICUAC group.
Moreover, the groups had different outcome profiles
when the patients were categorized according to
APACHE II scores. Non-ICUAC patients more often
had underlying co-morbidities, whereas ICUAC candide-
mia patients had more often undergone previous surgery
and all had central venous lines. Taken together, future
studies should account for the fact that ICUs are treat-
ing two different groups of candidemia patients.
Key messages
• More than half of the ICU-treated candidemias are
actually acquired before ICU admission. Candida
Ylipalosaari et al. Critical Care 2012, 16:R62
http://ccforum.com/content/16/2/R62
Page 7 of 9
albicans is still the most common cause of
candidemia.
• Patients with non-ICU-acquired candidemia have
different risk factors than patients with ICU onset
candidemia.
• Patients in the ICUAC group had significantly
higher maximum SOFA scores in coagulation, cardi-
ovascular, central nervous system and renal systems
than patients in the non-ICUAC group.
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